Shikuma N
Proc Natl Acad Sci U S A. 2025; 122(7):e2500342122.
PMID: 39928881
PMC: 11848427.
DOI: 10.1073/pnas.2500342122.
Janssen S, Murphy M, Upton C, Allwood B, Diacon A
Respirology. 2025; 30(3):196-205.
PMID: 39887565
PMC: 11872285.
DOI: 10.1111/resp.14887.
Rompp A, Treu A, Kokesch-Himmelreich J, Marwitz F, Dreisbach J, Aboutara N
Nat Commun. 2025; 16(1):826.
PMID: 39827265
PMC: 11742723.
DOI: 10.1038/s41467-025-56146-9.
Davids L, Crowley T
J Public Health Afr. 2025; 15(1):703.
PMID: 39822609
PMC: 11736563.
DOI: 10.4102/jphia.v15i1.703.
Lysenko V, Son S, Theriault M, Slingerland C, Hauk G, Cleenewerk L
Chemistry. 2024; 31(1):e202403767.
PMID: 39412482
PMC: 11711294.
DOI: 10.1002/chem.202403767.
An additional proofreader contributes to DNA replication fidelity in mycobacteria.
Deng M, Liu Q, Cui S, Wang Y, Zhu G, Fu H
Proc Natl Acad Sci U S A. 2024; 121(34):e2322938121.
PMID: 39141351
PMC: 11348249.
DOI: 10.1073/pnas.2322938121.
Multi-target Compounds against Trypanosomatid Parasites and .
Gomes M, Padilha E, Diniz G, Gomes E, Santos-Junior P, Zhan P
Curr Drug Targets. 2024; 25(9):602-619.
PMID: 38910467
DOI: 10.2174/0113894501306843240606114854.
Drug-Resistant Bone, Joint and Spine Tuberculosis: Evolution of Diagnosis and Treatment.
Jain A, Jain P, Jaggi K, Suresh A, Yadav M, Gain A
Indian J Orthop. 2024; 58(6):661-668.
PMID: 38812873
PMC: 11130086.
DOI: 10.1007/s43465-024-01138-y.
A host-directed oxadiazole compound potentiates antituberculosis treatment via zinc poisoning in human macrophages and in a mouse model of infection.
Maure A, Lawaree E, Fiorentino F, Pawlik A, Gona S, Giraud-Gatineau A
PLoS Biol. 2024; 22(4):e3002259.
PMID: 38683873
PMC: 11081512.
DOI: 10.1371/journal.pbio.3002259.
Lessons for TB from the COVID-19 response: qualitative data from Brazil, India and South Africa.
Myburgh H, Kaur M, Kaur P, Santos V, Almeida C, Hoddinott G
Public Health Action. 2023; 13(4):162-168.
PMID: 38077722
PMC: 10703135.
DOI: 10.5588/pha.23.0044.
Standards for clinical trials for treating TB.
du Cros P, Greig J, Alffenaar J, Cross G, Cousins C, Berry C
Int J Tuberc Lung Dis. 2023; 27(12):885-898.
PMID: 38042969
PMC: 10719894.
DOI: 10.5588/ijtld.23.0341.
Study protocol for safety and efficacy of all-oral shortened regimens for multidrug-resistant tuberculosis: a multicenter randomized withdrawal trial and a single-arm trial [SEAL-MDR].
Fu L, Xiong J, Wang H, Zhang P, Yang Q, Cai Y
BMC Infect Dis. 2023; 23(1):834.
PMID: 38012543
PMC: 10683225.
DOI: 10.1186/s12879-023-08644-8.
Revolutionizing control strategies against Mycobacterium tuberculosis infection through selected targeting of lipid metabolism.
Kim H, Shin S
Cell Mol Life Sci. 2023; 80(10):291.
PMID: 37704889
PMC: 11072447.
DOI: 10.1007/s00018-023-04914-5.
Association between overweight/obesity and multidrug-resistant tuberculosis.
Peinado J, Lecca L, Jimenez J, Calderon R, Yataco R, Becerra M
Rev Peru Med Exp Salud Publica. 2023; 40(1):59-66.
PMID: 37377237
PMC: 10953666.
DOI: 10.17843/rpmesp.2023.401.12138.
Application of Enantioselective Sulfur Ylide Epoxidation to a Short Asymmetric Synthesis of Bedaquiline, a Potent Anti-Tuberculosis Drug.
Bashir M, Arshad M, Begum R, Aggarwal V
Org Lett. 2023; 25(23):4281-4285.
PMID: 37284829
PMC: 10278180.
DOI: 10.1021/acs.orglett.3c01286.
At Long Last: Short, All-Oral Regimens for Multidrug-Resistant Tuberculosis in the United States.
Sinha P, Jacobson K, Horsburgh Jr C, Acuna-Villaorduna C
Open Forum Infect Dis. 2023; 10(4):ofad177.
PMID: 37125228
PMC: 10135426.
DOI: 10.1093/ofid/ofad177.
When it comes to stopping tuberculosis, what is actually "missing"?.
Fatah F, Furin J, Pai M
PLOS Glob Public Health. 2023; 2(3):e0000319.
PMID: 36962376
PMC: 10021630.
DOI: 10.1371/journal.pgph.0000319.
The effect of a postpartum intrauterine device programme on choice of contraceptive method in Tanzania: a secondary analysis of a cluster-randomized trial.
Senderowicz L, Sokol N, Pearson E, Francis J, Ulenga N, Barnighausen T
Health Policy Plan. 2022; 38(1):38-48.
PMID: 36330537
PMC: 9849716.
DOI: 10.1093/heapol/czac094.
Mycobacterium Time-Series Genome Analysis Identifies AAC2' as a Potential Drug Target with Naloxone Showing Potential Bait Drug Synergism.
Niranjan V, Uttarkar A, Murali K, Niranjan S, Gopal J, Kumar J
Molecules. 2022; 27(19).
PMID: 36234683
PMC: 9571707.
DOI: 10.3390/molecules27196150.
Identification of Concomitant Inhibitors against Glutamine Synthetase and Isocitrate Lyase in from Natural Sources.
Chanda A, Kalita S, Mishra A, Changkakoti L, Biswa Sarma J, Biswas K
Biomed Res Int. 2022; 2022:4661491.
PMID: 36225979
PMC: 9550479.
DOI: 10.1155/2022/4661491.
